Synthesis and evaluation of the anti-inflammatory activity of N-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-4-oxothiazolidin-3-yl]-nicotinamide

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 9, 2007, Pages 616-622

  Kalia, Rajiv ^a   Rao, Chamallamudi Mallikarjuna ^a   Gopalan Kutty, Nampurath ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Anti atherosclerotic drugs; Anti inflammatory drugs; Anti oxidants; N 2(3,5 Di tert butyl 4 hydroxyphenyl) 4 oxo thiazolidin 3 yl nicotinamide; Nicotinic acid derivative; Thiazolidin 4 ones

Indexed keywords

IBUPROFEN; N [2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 4 OXO THIAZOLIDIN 3 YL] NICOTINAMIDE; NICOTINAMIDE DERIVATIVE; UNCLASSIFIED DRUG; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CARRAGEENAN; COPPER; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; N (2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 4 OXO THIAZOLIDIN 3 YL) NICOTINAMIDE; N-(2-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)-4-OXO-THIAZOLIDIN-3-YL)-NICOTINAMIDE; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; DRUG SYNTHESIS; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; RAT; ANIMAL; ARTHRITIS; ATHEROSCLEROSIS; BLOOD; CHEMICALLY INDUCED DISORDER; EDEMA; GRANULOMA; INFLAMMATION; PATHOLOGY; SYNTHESIS; WISTAR RAT;

ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ARTHRITIS, EXPERIMENTAL; ASPARTATE AMINOTRANSFERASES; ATHEROSCLEROSIS; CARRAGEENAN; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EDEMA; GRANULOMA; IBUPROFEN; INDICATORS AND REAGENTS; INFLAMMATION; MALE; NIACINAMIDE; RATS; RATS, WISTAR;

EID: 35048818014     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296657     Document Type: Article

References (27)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-1143.
2. Forrester JS, Bick-Forrester J. Persistence of inflammatory cytokines cause a spectrum of chronic progressive diseases: Implications for the future therapy. Med J Hypothesis. 2005; 65(2): 227-231.
3. Xiu RJ, Freyschuss A, Ying X, Berglund L, Henriksson P, Bjorkhem I. The antioxidant butylated hydroxyltoluene prevents early cholesterol-induced microcirculatory changes in rabbits. J Clin Invest. 1994; 93(6): 2732-2737.
4. Jacob N, Kutty GN. Synthesis and hypolipidemic activity of a thiazolidin-4-one derivative. Indian Drugs. 2004; 41(2): 76-79.
5. Joy JM, Jacob N, Kutty GN. Evaluation of hypoglycemic effect of 4-thiazolidinones. Indian Drugs. 2005; 42(1): 47-51.
6. Conner EM, Grisham MB. Inflammation, free radicals and anti-oxidants. Nutrition. 1996; 12(4): 244-277.
7. El-Feky SA, Aldel-Sammizk. Synthesis and anti-inflammatory properties of some novel thiazolidinones and imidazolidinones derived from 4-(3-phenyl-4(-3H)-quinazolinon-2-yl)-3-thiosemicarbazone. Pharmazie. 1995; 50(5): 341-343.
8. Vigorita MG, Ottana R, Monforte F, Maccari R, Monforte MT, Trovato A, et al. Chiral 3,3′-(1,2-etanediyl)-bis[2-(3,4-dimethoxyphenyl)-4- thiazolidinones] with anti-inflammatory activity. Part 11: Evaluation of COX-2 selectivity and modeling. Bioorg Med Chem. 2003; 11(6): 999-1006.
9. Inagaki M, Matsumoto S, Tsuri T. Short synthesis of tert-butyl- hydroxylated 3,5-di-tert-butyl-4-hydroxybenzaldehyde: synthesis of tert-butyl-hydroxylated s-2474. J Org Chem. 2003; 68: 1128-1131.
10. Surrey AR. 4-Thiazolidinones IV: The preparation of some substituted 3-alkylamino-2-aryl derivatives. J Am Chem Soc. 1949; 71: 3354-3356.
11. Ghosh MN. Fundamentals of Experimental Pharmacology. 2nd ed. Calcutta: Scientific Book Agency; 1984.
12. Paget GE, Barnes JM. Toxicity studies. In: Laurence DA, Bacharach AL, eds. Evaluation of drug activities: Pharmacometrics. New York: Academic Press; 1964. p. 135-166.
13. Winter CA, Risley EA, Nauss GW. Carrageenan induced edema in hind paw of rats as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med. 1962; 111: 544-547.
14. Larry JP, Fogt SW, Ariyan ZS, Rippin DJ, Heilman RD, Mathews, RJ. Effect of structural change on acute toxicity and antiinflammatory activity in a series of imidazothiazoies and thiazolobenzimidazoles. J Med Chem. 1981; 24(5): 604-609.
15. D'Arcy PD, Howard EM, Muggleton PW. J Pharm Pharmacol. 1968; 12: 659.
16. Zak B, Landers JM. J Clin Path. 1958; 29: 590.
17. Bergmeyer HU, Scheibe P, Wahlefeld AW. Clin Chem Acta. 1976; 70: F 19.2.
18. Bergmeyer HU, Scheibe P, Wahlefeld AW. Clin Chem. 1978; 24: 58.
19. Henry RJ. Enzymes. In: Clinical Chemistry Principles & Techniques. New York: Harper and Row Publisher; 1974. p. 815.
20. Weichselbaum TE. Amer J Clin Path. 1946; 16: 40.
21. Weis WA. Klin Wschr. 1965; 43: 273.
22. Kato J, Ozaki T, Tamara K, Suzuki Y, Akima M, Ohi N. Novel calcium antagonist with both calcium overload inhibition and anti-oxidant activity. J Med Chem. 1998; 41(22): 4309-4316.
23. Panetta JA, Shadle JK, Phillips ML, Benslay DN, Ho PP. 4-Thiazolidinones, potent antioxidants as anti-inflammatory agents. Ann NY Acad Sci. 1993; 696: 415-416.
24. Vukicevic S, Marusic A, Stavljenic A, Cesnjaj M, Ivankovic D. The role of tumor necrosis factor in the generation of acute phase response and bone loss in rats with talc granulomatosis. Lab Invest. 1994; 70(3): 386-391.
25. Oktay C, Sukuru A. Serum zinc and copper levels in rheumatoid arthritis. J Islamic Acad Sci. 1997; 10(1): 19-24.
26. Neve J, Fontaine J, Peretz A, Famaey JP. Changes in zinc, copper and selenium status during adjuvant induced arthritis in rats. Agents Actions. 1988; 25(1-2): 146-155.
27. Lanigan RS, Yamarik TA. Final report on the safety assessment of BHT(1). Int J Toxicol. 2002; 2: 19-94.